期刊文献+

厄洛替尼治疗晚期非小细胞肺癌的临床研究

The Clinical Research of Erlotinib in Treatment of Advanced Non-small Cell Lung Cancer
下载PDF
导出
摘要 目的 探讨分析晚期非小细胞肺癌患者接受厄洛替尼治疗的临床效果,为临床中的治疗提供可靠的参考信息。方法 根据2012年12月~2014年12月我院的30例晚期非小细胞肺癌患者进行研究分析,使用厄洛替尼治疗,患者接受药物治疗后,对其毒副反应以及效果进行观察分析。结果 全部患者中有10例疾病进展,13例病情稳定,6例部分缓解,1例完全缓解,7例治疗有效。患者接受药物治疗后有皮疹、皮肤瘙痒、腹泻、恶心等毒副反应,均不严重,针对性的采取治疗措施后,均得到了缓解。结论 晚期非小细胞肺癌患者接受厄洛替尼治疗的临床效果突出,可能会出现较轻的毒副作用,但是针对性处理后可以缓解,均不严重。 Objective To investigate the clinical effect of advanced non receive erlotinib in patients with small cell hmg cancer, to provide a reliable reference infurmation for the clinical treatment. Methods According to the 30 cases from December 21112 to December 2014 in our hospital were stndied in patients with non sman cellhmg cancer, the use of erlotinib treatment, patients received drug treatment, obserwtion and analysis were carried out on the toxicity and etTect. Results There were 10 cases of disease progression in all patients, stable in 13 cases, partial remission in 6 cases, complete remission in 1 case, and effective treatment in 7 cases. Patients received drug treatment rash, skin itching, diarrhea, nausea and other side effects, are not serious, targeted to take treatment measures, have been alleviated. Conclusion Advanced non clinical effect to receive erlotinib in patieuts with small cell hmg cancer is promineut, there may be less side effects, but the treatment cau alleviate, not serious.
作者 颜莹 李江秋
出处 《中国卫生标准管理》 2016年第23期98-99,共2页 China Health Standard Management
关键词 厄洛替尼 晚期非小细胞肺癌 临床研究 Erlotinib, Adwmced non-smaU cell hmg cancer, Clinical research
  • 相关文献

参考文献8

二级参考文献63

  • 1邹燕梅,于世英.吉非替尼治疗晚期非小细胞肺癌临床研究[J].肿瘤防治研究,2008,35(S1):14-17. 被引量:3
  • 2朱正飞,樊旼,傅小龙,王丽娟,蒋国梁,赵森.非小细胞肺癌调强放射治疗的近期疗效和毒性反应[J].中国癌症杂志,2007,17(1):80-83. 被引量:4
  • 3李勇,张湘茹,孙燕.非小细胞肺癌的靶向治疗进展[J].癌症进展,2007,5(2):151-157. 被引量:19
  • 4Bezjak A, Shepherd F, Tu D, et al. Symptone response in non small cell lung cancer (NSCI.(7) patients treated with erlotinib qualityol life analysis of the NCIC CTG BR. 21 trial[C]. AS CO, 2005.
  • 5Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (the IDEAl.Trial)[J]. J Clin Oncol,2003,21 (12) :2237 2246.
  • 6Shepherd FA, Rodrigues J, Ciuleanu T, et al. Erlotinih in previously treated non small cell lung cancer[J]. N Engl J Med,2005,353(2):123-132.
  • 7Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer molecular and clinical predictorso foutcome[J]. N Engl J Med,2005,353 : 133-144.
  • 8Thatcher N, Chang A, Parikh P, et al. Gefitinih plus best supportive care in previously treated patients with refractory advanced non small-cell lung cancer: results from a random ised, placebo controlled .multicentre study (Iressa Survival Evaluation in Lung Cancer)[J]. Lancet,2005,366(9496): 1527- 1537.
  • 9Tang PA, Tsao MS, Moore MJ. A review of erlotinib and its clinical use. Expert Opin Pharmacother, 2006, (2): 177-193.
  • 10Silvestri GA, Rivera MP. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest, 2005. 128(6): 3975-3984.

共引文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部